Healthcare Industry News: Roche
News Release - October 6, 2017
Norbert Oppitz Joins Sobi(TM) as New Senior Vice President, Specialty CareSTOCKHOLM, Oct. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Norbert Oppitz has been appointed Senior Vice President for the newly established business area Specialty Care.
Norbert Oppitz brings considerable management experience from over 30 years in the Pharmaceutical and Healthcare Industry. Most recently he has been a member of the Executive Committee of BSN Medical in charge of Latin America. Beforehand, he was a member of the Executive Committee of Endo Pharmaceuticals where he was in charge of emerging markets. In previous capacities, he has led large organisations as Head of Latin America at Takeda/Nycomed as well as in country management roles at Roche Pharmaceuticals and Aventis Pharma.
"We are delighted that Norbert could join Sobi. Norbert is a true entrepreneur, and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our Specialty Care business," says Guido Oelkers, President and CEO of Sobi.
Norbert Oppitz will head Sobi's Specialty Care organisation and work closely together with Corporate Development and the regional and country organisations. Norbert will be part of Sobi's Executive Leadership Team.
"I am excited to join Sobi – a company with a strong, patient-centric profile and a great potential. I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital Specialty Care business unit," says Norbert.
Norbert Oppitz joined Sobi on 2 October 2017.
Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
Source: Swedish Orphan Biovitrum
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.